Daily Courier: Single Column

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Anaptysbio Inc (NQ: ANAB )

37.75 +0.46 (+1.23%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 252,099
Open 37.51
Bid (Size) 15.05 (2)
Ask (Size) 38.80 (1)
Prev. Close 37.29
Today's Range 36.72 - 38.05
52wk Range 13.36 - 41.31
Shares Outstanding 27,433,359
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why AnaptysBio Was Such a Healthy Stock This Week
The company's immediate future looks promising, as it has a drug that should get a clinical readout within months and a deep-pocketed pharmaceutical peer as an investor. 
Via The Motley Fool
Insiders Buying Yum China And 2 Other Stocks
Via Benzinga

Performance

YTD
+73.96%
+73.96%
1 Month
+2.30%
+2.30%
3 Month
+57.88%
+57.88%
6 Month
+45.92%
+45.92%
1 Year
+86.42%
+86.42%

More News

Read More
UBS Posts Upbeat Earnings, Joins Victoria's Secret, Performance Food Group, Kellanova And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
AnaptysBio Hits Five-Year High After Sanofi Takes A Stake In $100 Million Offering
Via Investor's Business Daily
S&P 500 Rises, Small Caps Outperform As July Consumer Price Index Fuels Fed Rate Cut Hopes: 5 ETFs to Watch Wednesday
Via Benzinga
Topics ETFs Economy Stocks
Exposures Interest Rates US Equities
4 Analysts Assess AnaptysBio: What You Need To Know
Via Benzinga
The Analyst Landscape: 7 Takes On AnaptysBio
Via Benzinga
Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering
From AnaptysBio, Inc.
Via GlobeNewswire
ANAB Stock Earnings: AnaptysBio Misses EPS, Misses Revenue for Q2 2024
Via InvestorPlace
Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update
From AnaptysBio, Inc.
Via GlobeNewswire
AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst
Via Benzinga
Unveiling 4 Analyst Insights On AnaptysBio
Via Benzinga
ANAB Stock Earnings: AnaptysBio Misses EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update
From AnaptysBio, Inc.
Via GlobeNewswire
Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
From AnaptysBio, Inc.
Via GlobeNewswire
Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties
From AnaptysBio, Inc.
Via GlobeNewswire
BTIG Research Predicts Over 118% Rally for These 3 Stocks
Via InvestorPlace
Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week
Via The Motley Fool
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Topics Stocks
Exposures US Equities
Skin Disease-Focused AnaptysBio Earns Analyst Upgrade On Positive Outlook For Clinical Triggers
Via Benzinga
Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From AnaptysBio, Inc.
Via GlobeNewswire
Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting
From AnaptysBio, Inc.
Via GlobeNewswire
Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference
From AnaptysBio, Inc.
Via GlobeNewswire
Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals
From AnaptysBio, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

© Copyright 2015, Daily Courier, Kelowna, BC. Powered by BLOX Content Management System from TownNews.com.